XML 44 R22.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Share-Based Compensation (Notes) | 12 Months Ended
--- | ---
Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] |
Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | Share-Based Compensation Share-based compensation expense is included in ‘compensation and benefits’ in the consolidated income statements and totaled $6.3 million, $5.1 million and $3.6 million for the fiscal years ended September 30, 2017, 2016, and 2015, respectively. Stock Option Plans The Company sponsors a stock option plan for its directors, officers, employees and consultants. The 2013 Stock Option Plan, which was approved by the Company’s Board of Directors and shareholders, authorizes the Company to issue stock options covering up to 1.0 million shares of the Company’s common stock. As of September 30, 2017, there were 0.7 million shares authorized for future grant under this plan. Awards that expire or are canceled generally become available for issuance again under the plan. The Company settles stock option exercises with newly issued shares of common stock. Fair value is estimated at the grant date based on a Black-Scholes-Merton option-pricing model using the following weighted-average assumptions:
| Year Ended September 30,
| 2017 |  | 2016 |  | 2015
Expected stock price volatility | 31 | % |  | 28 | % |  | 28 | %
Expected dividend yield | — | % |  | — | % |  | — | %
Risk free interest rate | 0.99 | % |  | 0.83 | % |  | 0.66 | %
Average expected life (in years) | 3.08 |  |  | 3.06 |  |  | 3.22 |
Expected stock price volatility rates are primarily based on the historical volatility. The Company has not paid dividends in the past and does not currently expect to do so in the future. Risk free interest rates are based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option or award. The average expected life represents the estimated period of time that options or awards granted are expected to be outstanding, based on the Company’s historical share option exercise experience for similar option grants. The weighted average fair value of options issued during fiscal years ended September 30, 2017, 2016, and 2015 was $8.67, $6.40 and $4.31, respectively. The following is a summary of stock option activity for the year ended September 30, 2017:
| Shares Available for Grant |  | Number of Options Outstanding |  | Weighted Average Exercise Price |  | Weighted Average Grant Date Fair Value |  | Weighted Average Remaining Term (in years) |  | Aggregate Intrinsic Value ($ millions)
Balances at September 30, 2016 | 754,163 |  |  | 1,215,821 |  |  | $ | 29.55 |  |  | $ | 12.88 |  |  | 3.80 |  | $ | 14.1 |
Granted | (110,000 | ) |  | 110,000 |  |  | $ | 38.77 |  |  | $ | 8.67 |  |  |  |  |
Exercised |  |  | (155,588 | ) |  | $ | 22.54 |  |  | $ | 9.05 |  |  |  |  |
Forfeited | 8,331 |  |  | (106,996 | ) |  | $ | 26.15 |  |  | $ | 13.20 |  |  |  |  |
Expired |  |  | (181,834 | ) |  | $ | 54.02 |  |  | $ | 19.93 |  |  |  |  |
Balances at September 30, 2017 | 652,494 |  |  | 881,403 |  |  | $ | 27.31 |  |  | $ | 11.55 |  |  | 3.57 |  | $ | 9.8 |
Exercisable at September 30, 2017 |  |  | 222,116 |  |  | $ | 24.42 |  |  | $ | 10.43 |  |  | 2.52 |  | $ | 3.1 |
The total compensation cost not yet recognized for non-vested awards of $3.9 million as of September 30, 2017 has a weighted-average period of 3.92 years over which the compensation expense is expected to be recognized. The total intrinsic value of options exercised during fiscal years 2017, 2016 and 2015 was $2.6 million, $1.9 million and $3.6 million, respectively. The options outstanding as of September 30, 2017 broken down by exercise price are as follows:
Exercise Price |  | Number of Options Outstanding |  | Weighted Average Exercise Price |  | Weighted Average Remaining Term (in Years)
$ | — |  | - | $ | 5.00 |  |  | — |  |  | n/a |  |  | n/a
$ | 5.00 |  | - | $ | 10.00 |  |  | — |  |  | n/a |  |  | n/a
$ | 10.00 |  | - | $ | 15.00 |  |  | — |  |  | n/a |  |  | n/a
$ | 15.00 |  | - | $ | 20.00 |  |  | 22,414 |  |  | $ | 19.24 |  |  | 0.30
$ | 20.00 |  | - | $ | 25.00 |  |  | 97,911 |  |  | $ | 21.77 |  |  | 0.84
$ | 25.00 |  | - | $ | 30.00 |  |  | 580,000 |  |  | $ | 25.91 |  |  | 4.37
$ | 30.00 |  | - | $ | 35.00 |  |  | 73,578 |  |  | $ | 31.37 |  |  | 2.28
$ | 35.00 |  | - | $ | 40.00 |  |  | 107,500 |  |  | $ | 38.77 |  |  | 3.27
$ | 40.00 |  | - | $ | 45.00 |  |  | — |  |  | n/a |  |  | n/a
$ | 45.00 |  | - | $ | 50.00 |  |  | — |  |  | n/a |  |  | n/a
$ | 50.00 |  | - | $ | 55.00 |  |  | — |  |  | n/a |  |  | n/a
|  |  |  | 881,403 |  |  | $ | 27.31 |  |  | 3.57
Restricted Stock Plan The Company sponsors a restricted stock plan for its directors, officers and employees. The Company’s 2017 restricted stock plan, which was approved by the Company’s Board of Directors and shareholders, authorizes up to 1.5 million shares to be issued. As of September 30, 2017, 1.5 million shares were authorized for future grant under the restricted stock plan. Awards that expire or are canceled generally become available for issuance again under the plan. The Company utilizes newly issued shares of common stock to make restricted stock grants. The following is a summary of restricted stock activity through September 30, 2017:
| Shares Available for Grant |  | Number of Shares Outstanding |  | Weighted Average Grant Date Fair Value |  | Weighted Average Remaining Term (in years) |  | Aggregate Intrinsic Value ($ millions)
Balances at September 30, 2016 | 747,782 |  |  | 357,752 |  |  | $ | 27.39 |  |  | 1.39 |  | $ | 13.9 |
Additional shares authorized by shareholders | 1,500,000 |  |  |  |  |  |  |  |  |
Termination of 2012 plan | (640,539 | ) |  |  |  |  |  |  |  |
Granted | (147,726 | ) |  | 147,726 |  |  | $ | 40.98 |  |  |  |  |
Vested |  |  | (150,545 | ) |  | $ | 26.69 |  |  |  |  |
Forfeited | 459 |  |  | (459 | ) |  | $ | 37.31 |  |  |  |  |
Balances at September 30, 2017 | 1,459,976 |  |  | 354,474 |  |  | $ | 33.34 |  |  | 1.26 |  | $ | 13.6 |
The total compensation cost not yet recognized of $8.2 million as of September 30, 2017 has a weighted-average period of 1.26 years over which the compensation expense is expected to be recognized. Compensation expense is amortized on a straight-line basis over the vesting period. Restricted stock grants are included in the Company’s total issued and outstanding common shares.

X
- Definition The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 50 -URI http://asc.fasb.org/subtopic&trid=2208855 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration